Ihre Browserversion ist veraltet. Wir empfehlen, Ihren Browser auf die neueste Version zu aktualisieren.

Novel Treatment Options


During the first funding period, we exchanged mouse models to test new therapeutic strategies and established a tool for the generation of transgenic mice. Now we will focus on the development of a promising therapeutic approach which has the potential to be applicable for a large group of patients with mutations in either nuclear or mitochondrial genomes that give raise to complex I defect, the most frequent biochemical diagnosis. We will apply strategies to bypass the complex I deficiency by utilizing alternative NADH dehydrogenases by transgenic proof-of-principle combined with a therapy-directed protein transduction approach. The feasibility of a bypass approach has been demonstrated in cell lines by us and others. In vivo approaches have been not described yet for complex I bypassing in mouse. To test the feasibility of this approach, we will address the following specific objectives:

i) to examine genetic expression of alternative NADH dehydrogenase NDI1 and NDH2 as complex I bypassing strategy in murine models,

ii) to assess mitochondrial protein transduction of alternative NADH dehydrogenase NDI1 and NDH2 as complex I bypassing strategy in murine models .

Cookie Policy

This site uses cookies to store information on your computer.

Do you accept?